Core Viewpoint - Xuan Bamboo Biotech-B (02575.HK) is set to launch its global offering from October 6 to October 10, 2025, with a proposed share price of HKD 11.6 per share, aiming to raise funds for its innovative drug development in oncology and other fields [2] Group 1: Company Overview - Xuan Bamboo Biotech is one of the few high-tech biopharmaceutical companies in China that possesses capabilities in the development, industrialization, and commercialization of both small molecule drugs and large molecule biologics [2] - The company is focused on innovative drug development in areas such as oncology, digestive diseases, and NASH, with over ten drug assets currently under active development [2] Group 2: Financial Performance - The company reported revenues of RMB 29 million, RMB 300.9 million, RMB 65.1 million, and RMB 25.6 million for the years 2023, 2024, and the three months ending March 31, 2025, respectively, with all income derived from the commercialization of its drug KBP-3571 [2] - Research and development expenditures for the years 2023, 2024, and the three months ending March 31, 2025, were RMB 239.06 million, RMB 186.40 million, RMB 38.89 million, and RMB 53.04 million, respectively [3] - The company is currently operating at a loss, with net losses of RMB 300.6 million, RMB 556.4 million, RMB 111.0 million, and RMB 110.9 million for the years 2023, 2024, and the six months ending June 30, 2025, primarily due to the early stage of its commercialization strategy and operational expenses incurred during the reporting periods [3]
轩竹生物开始招股 主要聚焦肿瘤、消化创新药